- Home
- COR
COR
Cencora Inc.
as of 12-05-2025 3:57pm EST
$339.01
+$1.38
+0.41%
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Chart Type:
Time Range:
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | CONSHOHOCKEN |
| Market Cap: | 57.4B | IPO Year: | N/A |
| Target Price: | $351.08 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.96 | EPS Growth: | 5.71 |
| 52 Week Low/High: | $223.92 - $377.54 | Next Earning Date: | 11-05-2025 |
| Revenue: | $321,332,819,000 | Revenue Growth: | 9.31% |
| Revenue Growth (this year): | 7.04% | Revenue Growth (next year): | 6.48% |
AI-Powered COR Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 86.81%
86.81%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Cencora Inc. (COR)
Mauch Robert P.
Sell
President & CEO
COR Nov 18, 2025
Avg Cost/Share
$366.64
Shares
5,096
Total Value
$1,868,397.44
Owned After
65,746
SEC Form 4
Mauch Robert P.
Sell
President & CEO
COR Oct 20, 2025
Avg Cost/Share
$326.80
Shares
5,097
Total Value
$1,665,699.60
Owned After
65,746
SEC Form 4
Campbell Elizabeth S
Sell
Executive Vice President
COR Oct 1, 2025
Avg Cost/Share
$313.28
Shares
1,886
Total Value
$590,846.08
Owned After
12,824.141
SEC Form 4
Mauch Robert P.
Sell
President & CEO
COR Sep 18, 2025
Avg Cost/Share
$290.00
Shares
5,097
Total Value
$1,478,130.00
Owned After
65,746
SEC Form 4
COLLIS STEVEN H
Sell
Executive Chairman
COR Sep 16, 2025
Avg Cost/Share
$289.86
Shares
31,350
Total Value
$9,087,142.35
Owned After
305,912.665
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Mauch Robert P. | COR | President & CEO | Nov 18, 2025 | Sell | $366.64 | 5,096 | $1,868,397.44 | 65,746 | |
| Mauch Robert P. | COR | President & CEO | Oct 20, 2025 | Sell | $326.80 | 5,097 | $1,665,699.60 | 65,746 | |
| Campbell Elizabeth S | COR | Executive Vice President | Oct 1, 2025 | Sell | $313.28 | 1,886 | $590,846.08 | 12,824.141 | |
| Mauch Robert P. | COR | President & CEO | Sep 18, 2025 | Sell | $290.00 | 5,097 | $1,478,130.00 | 65,746 | |
| COLLIS STEVEN H | COR | Executive Chairman | Sep 16, 2025 | Sell | $289.86 | 31,350 | $9,087,142.35 | 305,912.665 |
Latest Cencora Inc. News
COR Breaking Stock News: Dive into COR Ticker-Specific Updates for Smart Investing
Insider Monkey
JPMorgan Raises Cencora (COR) Price Target After Financial Model Update
📈
AI Sentiment
Highly Positive
8/10
Business Wire
Cencora Enhances Global Pharmaceutical Logistics Services, Cold Chain Capabilities
📈
AI Sentiment
Highly Positive
8/10
Barchart
How Is Cencora’s Stock Performance Compared to Other Medical Stocks?
📈
AI Sentiment
Highly Positive
8/10
Compare COR vs Leading Stocks
See how COR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "COR Cencora Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.